Clinical Trial Update: Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Aroxxen inhalation for cardioprotection after elective PCI with stent implantation; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Aroxxen

Snippet

Sponsor: Research Institute of Geroprotective Technologies | Conditions: Coronary Artery Disease | Phase 2 | Status: NOT_YET_RECRUITING